| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
144,135,000 |
| Market
Cap: |
8.68(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,204,320 |
| 52
Week Range: |
$29.84 - $68.15 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1083 |
| Guru Rank Value : 0 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
96,274 |
165,407 |
449,912 |
879,667 |
| Total Sell Value |
$6,233,380 |
$9,939,277 |
$21,536,030 |
$47,209,596 |
| Total People Sold |
7 |
8 |
10 |
11 |
| Total Sell Transactions |
14 |
31 |
75 |
125 |
| End Date |
2025-11-06 |
2025-08-05 |
2025-02-04 |
2024-02-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2026-02-05 |
4 |
S |
$61.93 |
$928,950 |
D/D |
(15,000) |
50,440 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2026-02-05 |
4 |
OE |
$23.26 |
$348,900 |
D/D |
15,000 |
65,440 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2026-02-02 |
4 |
S |
$62.10 |
$55,021 |
D/D |
(886) |
50,440 |
|
3% |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2026-02-02 |
4 |
OE |
$37.63 |
$33,340 |
D/D |
886 |
51,326 |
|
- |
|
| Daly James M |
Director |
• • – |
2026-01-15 |
4 |
A |
$63.44 |
$12,498 |
D/D |
197 |
197 |
|
- |
|
| Wierenga Wendell |
Director |
• • – |
2026-01-15 |
4 |
A |
$63.44 |
$6,217 |
D/D |
98 |
32,542 |
|
- |
|
| Kaye Edward M. Md |
Director |
• • – |
2026-01-15 |
4 |
A |
$63.44 |
$12,498 |
D/D |
197 |
10,174 |
|
- |
|
| Wysenski Nancy |
Director |
• • – |
2026-01-15 |
4 |
A |
$63.44 |
$6,217 |
D/D |
98 |
30,971 |
|
- |
|
| Harrington Robert Arthur |
Director |
• • – |
2026-01-15 |
4 |
A |
$63.44 |
$12,498 |
D/D |
197 |
18,739 |
|
- |
|
| Henderson John T |
Director |
• • – |
2026-01-15 |
4 |
A |
$63.44 |
$21,189 |
D/D |
334 |
74,912 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2026-01-05 |
4 |
S |
$60.28 |
$904,200 |
D/D |
(15,000) |
50,440 |
|
-4% |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2026-01-05 |
4 |
OE |
$23.26 |
$348,900 |
D/D |
15,000 |
65,440 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2026-01-02 |
4 |
S |
$62.09 |
$112,585 |
D/D |
(1,798) |
50,440 |
|
-3% |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2026-01-02 |
4 |
OE |
$37.63 |
$33,303 |
D/D |
885 |
51,325 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-12-29 |
4 |
S |
$62.44 |
$112,954 |
D/D |
(1,809) |
51,353 |
|
-3% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-12-22 |
4 |
D |
$62.72 |
$63,724 |
D/D |
(1,016) |
141,536 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
142,552 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-12-22 |
4 |
D |
$62.72 |
$42,336 |
D/D |
(675) |
53,162 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,177 |
53,837 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-12-22 |
4 |
D |
$62.72 |
$184,083 |
D/D |
(2,935) |
399,604 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
11,530 |
402,539 |
|
- |
|
| Lee Sung |
EVP, Chief Financial Officer |
• • – |
2025-12-22 |
4 |
D |
$62.72 |
$50,490 |
D/D |
(805) |
71,416 |
|
- |
|
| Lee Sung |
EVP, Chief Financial Officer |
• • – |
2025-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,304 |
72,221 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-12-22 |
4 |
OE |
$6.67 |
$475,124 |
D/D |
71,233 |
391,009 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-12-22 |
4 |
D |
$68.18 |
$2,074,445 |
D/D |
(30,426) |
374,503 |
|
- |
|
976 Records found
|
|
Page 1 of 40 |
|
|
3.28 (5.16%) 
